CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. (Record no. 17421143)

MARC details
000 -LEADER
fixed length control field 01313 a2200361 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250515090424.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200710s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1743-4262
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1038/ncponc0931
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Pan, Minggui
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20071031
245 00 - TITLE STATEMENT
Title CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Nature clinical practice. Oncology
Date of publication, distribution, etc. Oct 2007
300 ## - PHYSICAL DESCRIPTION
Extent 603-7 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Case Reports; Journal Article
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Agents
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Brain Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carcinoma, Non-Small-Cell Lung
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element ErbB Receptors
General subdivision antagonists & inhibitors
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Erlotinib Hydrochloride
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Lung Neoplasms
General subdivision genetics
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Mutation
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Protein Kinase Inhibitors
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Quinazolines
General subdivision therapeutic use
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Santamaria, Monica
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Wollman, David B
773 0# - HOST ITEM ENTRY
Title Nature clinical practice. Oncology
Related parts vol. 4
-- no. 10
-- p. 603-7
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1038/ncponc0931">https://doi.org/10.1038/ncponc0931</a>
Public note Available from publisher's website

No items available.